1412

Basic information

Introducing the EarlyTect Colon Cancer Test, a groundbreaking product designed specifically for the early detection of colorectal cancer. This test has received approval from the prestigious Korea Ministry of Food and Drug Safety after undergoing rigorous clinical trials at renowned medical institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

Clinical trials involving 585 men and women aged 30 to 80 have shown that the EarlyTect Colon Cancer Test can diagnose colorectal cancer with an impressive accuracy rate of 90% in terms of sensitivity and specificity. By utilizing fecal DNA and conducting qualitative real-time PCR tests, this innovative screening tool measures the presence of methylated Syndecan-2, a crucial biomarker clinically associated with precancerous lesions of colorectal cancer.

It is important to note that while the EarlyTect Colon Cancer Test is highly effective in identifying potential cases of colorectal cancer, its purpose is not to confirm the diagnosis. In the event of a positive result, there is a possibility that colorectal cancer or precancerous lesions of colorectal cancer may be present. Therefore, further medical consultation and diagnostic procedures are recommended.

Product Standard:

- Cancer Type: Colorectal Cancer
- Subject: Suitable for asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 me

To obtain pricing information and discuss transaction conditions, we encourage you to request a quote. Our team is flexible and committed to meeting your specific requirements.